CLINICAL TRIAL CONTRACT WITH MEDICINAL PRODUCTS Protocol Code: [•] EudraCT: [•]Clinical Trial Contract • August 3rd, 2021
Hospital Universitari Vall d’Hebron (hereinafter, “HUVH”), with address at Passeig Vall d’Hebron 119-129, Barcelona (08035), represented by Dr. Albert Salazar i Soler, in his capacity as Director of the centre of the HUVH.
CLINICAL TRIAL CONTRACT […] (Protocol Code)Clinical Trial Contract • August 1st, 2016
Hospital Universitari Vall d’Hebron (hereinafter, ‘HUVH’), with address in Passeig Vall d’Hebron 119-129, Barcelona (08035) represented by Dr Vicenç Martínez Ibáñez, holder of national identity document (DNI) 38532268-T, in his capacity as HUVH General Manager.
「□□□□□□□□」(Protocol Title) Clinical Trial ContractClinical Trial Contract • October 10th, 2020
Institution: Taipei Medical University (representative), Taipei Medical University Hospital, Taipei Medical University Municipal Wan Fang Hospital, and Taipei Medical University Shuang Ho Hospital (Here after known as “Institution”).
DODATEK Č. 1 KE SMLOUVĚ O PROVEDENI KLINICKÉHO HODNOCENÍClinical Trial Contract • August 28th, 2020
AMENDMENT #1 ("Contract Amendment # l"), valid as of the last signature date below and effective as of the date of publication in the Registry of Contracts (the "Effective Date"), by and between
ADDENDUM Nº. [...] TO CLINICAL THE TRIAL CONTRACT […]Clinical Trial Contract • November 23rd, 2020
The first party, the Hospital Universitari Vall d’Hebron (hereinafter the "HUVH"), with address in Passeig Vall d'Hebron 119-129, Barcelona (08035) represented by Dr. Vicenç Martínez Ibáñez, with I.D. No. 38532268T, as HUVH Manager.
CLINICAL TRIAL CONTRACTClinical Trial Contract • February 1st, 2022
The first party: Dr. José Luis de Sancho Martín, with Spanish D.N.I. number 02480269H, Manager of the Hospital Universitari Vall d'Hebron, Barcelona (SPAIN), on behalf of the Institution),
CLINICAL TRIAL CONTRACTClinical Trial Contract • January 14th, 2021
THIS CONTRACT, effective the [ DATE ] day of [ MONTH ], 199[ YEAR ] (hereinafter the "Effective Date"), is entered into by and between ________________________ (hereinafter "School") and [ NAME OF SPONSOR ], a [ STATE OF INCORPORATION ] Corporation, with principal offices located at [ ADDRESS ] (hereinafter "Sponsor"), governing research to be conducted at School in the laboratories and clinic of [ NAME OF INVESTIGATOR AT SCHOOL ] (hereinafter "Principal Investigator").
